George Peoples - 01 Jul 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Director
Signature
/s/ Andrew Jackson, Attorney-in-fact
Issuer symbol
CLDI
Transactions as of
01 Jul 2024
Net transactions value
$0
Form type
4
Filing time
11 Jul 2024, 16:53:47 UTC
Next filing
15 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDI Non-Qualified Stock Options (right to buy) Award +30,904 30,904 01 Jul 2024 Common stock 30,904 $0.1930 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on July 1, 2024 (the "Grant Date"), the Reporting Person was granted 30,904 non-qualified stock options (the "Options") at the exercise price of $0.193, which is the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/36 per month over three years, commencing on the Grant Date.

Remarks:

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 3 dated July 8, 2024.)